Trials / Completed
CompletedNCT00185328
Efficacy and Tolerability of Angeliq in Thai Women
A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Estradiol/DRSP (Angeliq, BAY86-4891) | 1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles |
Timeline
- Start date
- 2005-09-01
- Completion
- 2006-12-01
- First posted
- 2005-09-16
- Last updated
- 2008-12-12
Source: ClinicalTrials.gov record NCT00185328. Inclusion in this directory is not an endorsement.